Redaporfin

Star0

DB17219InvestigationalSmall molecule

Redaporfin: Overview.

Formula / weight: C₄₈H₃₈F₈N₈O₈S₄ · 1135.11 g/mol (avg)
Code names: F2BMET · LUZ-11

Resolves to

Compound

UNIIZP3QP1H44WCAS1224104-08-8

Structure

InChIKeyCKRVBMUJCFKRND-ZXWMLXKTSA-NSMILES

CNS(=O)(=O)C1=CC=C(F)C(=C1F)C1=C2\CCC(=N2)\C(=C2/N\C(\C=C2)=C(/C2=N/C(/CC2)=C(\C2=CC=C\1N2)C1=C(F)C(=CC=C1F)S(=O)(=O)NC)C1=C(F)C(=CC=C1F)S(=O)(=O)NC)\C1=C(F)C(=CC=C1F)S(=O)(=O)NC

Transporters

P08183ABCB1

What you can answer from here — as of July 11, 2026

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Redaporfin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account